These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

410 related items for PubMed ID: 489

  • 1. The neurochemistry of Parkinson's disease: effect of L-dopa therapy.
    Lloyd KG, Davidson L, Hornykiewicz O.
    J Pharmacol Exp Ther; 1975 Dec; 195(3):453-64. PubMed ID: 489
    [Abstract] [Full Text] [Related]

  • 2. Coadministration of β-asarone and levodopa increases dopamine in rat brain by accelerating transformation of levodopa: a different mechanism from Madopar.
    Huang L, Deng M, Zhang S, Fang Y, Li L.
    Clin Exp Pharmacol Physiol; 2014 Sep; 41(9):685-90. PubMed ID: 24910244
    [Abstract] [Full Text] [Related]

  • 3. BIA 3-202, a novel catechol-O-methyltransferase inhibitor, enhances the availability of L-DOPA to the brain and reduces its O-methylation.
    Parada A, Loureiro AI, Vieira-Coelho MA, Hainzl D, Soares-da-Silva P.
    Eur J Pharmacol; 2001 May 18; 420(1):27-32. PubMed ID: 11412836
    [Abstract] [Full Text] [Related]

  • 4. Parkinson's disease: from brain homogenate to treatment.
    Hornykiewicz O.
    Fed Proc; 1973 Feb 18; 32(2):183-90. PubMed ID: 4143953
    [No Abstract] [Full Text] [Related]

  • 5. Peculiarities of L: -DOPA treatment of Parkinson's disease.
    Kostrzewa RM, Nowak P, Kostrzewa JP, Kostrzewa RA, Brus R.
    Amino Acids; 2005 Mar 18; 28(2):157-64. PubMed ID: 15750845
    [Abstract] [Full Text] [Related]

  • 6. Effects of acute and sub-chronic L-dopa therapy on striatal L-dopa methylation and dopamine oxidation in an MPTP mouse model of Parkinsons disease.
    Smith ML, King J, Dent L, Mackey V, Muthian G, Griffin B, Charlton CG.
    Life Sci; 2014 Aug 06; 110(1):1-7. PubMed ID: 24880075
    [Abstract] [Full Text] [Related]

  • 7. L-Dihydroxyphenylalanine modulates the steady-state expression of mouse striatal tyrosine hydroxylase, aromatic L-amino acid decarboxylase, dopamine and its metabolites in an MPTP mouse model of Parkinson's disease.
    King JM, Muthian G, Mackey V, Smith M, Charlton C.
    Life Sci; 2011 Oct 24; 89(17-18):638-43. PubMed ID: 21871902
    [Abstract] [Full Text] [Related]

  • 8. Effects of 3-O-methyldopa, L-3,4-dihydroxyphenylalanine metabolite, on locomotor activity and dopamine turnover in rats.
    Onzawa Y, Kimura Y, Uzuhashi K, Shirasuna M, Hirosawa T, Taogoshi T, Kihira K.
    Biol Pharm Bull; 2012 Oct 24; 35(8):1244-8. PubMed ID: 22863920
    [Abstract] [Full Text] [Related]

  • 9. Peripheral and central inhibitors of catechol-O-methyl transferase: effects on liver and brain COMT activity and L-DOPA metabolism.
    Brannan T, Prikhojan A, Yahr MD.
    J Neural Transm (Vienna); 1997 Oct 24; 104(1):77-87. PubMed ID: 9085195
    [Abstract] [Full Text] [Related]

  • 10. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
    Lyytinen J, Kaakkola S, Ahtila S, Tuomainen P, Teräväinen H.
    Mov Disord; 1997 Jul 24; 12(4):497-505. PubMed ID: 9251066
    [Abstract] [Full Text] [Related]

  • 11. Serotonergic neurones are not involved in action of L-dopa in Parkinson's disease.
    Melamed E, Hefti F, Liebman J, Schlosberg AJ, Wurtman RJ.
    Nature; 1980 Feb 21; 283(5749):772-4. PubMed ID: 6101905
    [No Abstract] [Full Text] [Related]

  • 12. Comparison of short and long-lasting effects of pargyline on cerebral dopamine metabolism.
    Waldmeier PC, Maître L.
    Naunyn Schmiedebergs Arch Pharmacol; 1976 Aug 21; 294(2):133-40. PubMed ID: 1012333
    [Abstract] [Full Text] [Related]

  • 13. L-dopa upregulates the expression and activities of methionine adenosyl transferase and catechol-O-methyltransferase.
    Zhao WQ, Latinwo L, Liu XX, Lee ES, Lamango N, Charlton CG.
    Exp Neurol; 2001 Sep 21; 171(1):127-38. PubMed ID: 11520127
    [Abstract] [Full Text] [Related]

  • 14. [Biochemical bases of Parkinson disease].
    Colucci d'Amato C, Puccini A, Cristillo A, Vizioli R.
    Recenti Prog Med; 1984 Oct 21; 75(10):889-901. PubMed ID: 6151219
    [No Abstract] [Full Text] [Related]

  • 15. L-DOPA: from a biologically inactive amino acid to a successful therapeutic agent.
    Hornykiewicz O.
    Amino Acids; 2002 Oct 21; 23(1-3):65-70. PubMed ID: 12373520
    [Abstract] [Full Text] [Related]

  • 16. Favorable effect of catechol-O-methyltransferase inhibition by OR-462 in experimental models of Parkinson's disease.
    Lindén IB, Nissinen E, Etemadzadeh E, Kaakkola S, Männistö P, Pohto P.
    J Pharmacol Exp Ther; 1988 Oct 21; 247(1):289-93. PubMed ID: 3171977
    [Abstract] [Full Text] [Related]

  • 17. 3-O-methyldopa blocks dopa metabolism in rat corpus striatum.
    Reches A, Fahn S.
    Ann Neurol; 1982 Sep 21; 12(3):267-71. PubMed ID: 7137962
    [Abstract] [Full Text] [Related]

  • 18. The metabolism of L-DOPA and L-threo-3,4-dihydroxyphenylserine and their effects on monoamines in the human brain: analysis of the intraventricular fluid from parkinsonian patients.
    Maruyama W, Naoi M, Narabayashi H.
    J Neurol Sci; 1996 Jul 21; 139(1):141-8. PubMed ID: 8836986
    [Abstract] [Full Text] [Related]

  • 19. Role of aromatic L-amino acid decarboxylase for dopamine replacement by genetically modified fibroblasts in a rat model of Parkinson's disease.
    Wachtel SR, Bencsics C, Kang UJ.
    J Neurochem; 1997 Nov 21; 69(5):2055-63. PubMed ID: 9349551
    [Abstract] [Full Text] [Related]

  • 20. The mechanism of perturbation in monoamine metabolism by L-dopa therapy: in vivo and in vitro studies.
    Maruyama W, Naoi M, Takahashi A, Watanabe H, Konagaya Y, Mokuno K, Hasegawa S, Nakahara D.
    J Neural Transm Gen Sect; 1992 Nov 21; 90(3):183-97. PubMed ID: 1363050
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.